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Objectives 
We aimed to evaluate the cost-effectiveness of aflibercept and bevacizumab 
compared to ranibizumab for the treatment of macular oedema (MO) secondary to 
central retinal vein occlusion (CRVO) in a within-trial cost-utility analysis. The 
analysis used data from the LEAVO study, a UK-based, multicentre, double-masked, 
randomised, non-inferiority trial. 
 
Methods 
Health-related quality of life (HRQoL) data were measured using the Visual-
Functioning Questionnaire Utility Index (VFQ-UI), EQ-5D and EQ-5D with vision bolt-
on (EQ-5D V), at baseline, 12, 24, 52, 76 and 100 weeks. Resource use data were 
collected using a bespoke, patient reported questionnaire. A within trial cost-utility 
analysis was carried out from the UK NHS and Personal Social Services 
perspective. Costs and QALYs were discounted at 3.5% annually. In the base-case 
analysis, utilities were calculated using the VFQ-UI. In sensitivity analyses, drug 
costs for ranibizumab and aflibercept were discounted at 30% and 50% and utilities 
were calculated using the EQ-5D questionnaires. 
 
Results 
In the base-case analysis, there were small, but uncertain, differences in QALYs 
between the three treatments. The difference in costs between aflibercept and 
ranibizumab was £1245 (95% confidence interval [CI]: £421, £2070), between 
bevacizumab and ranibizumab was -£6760 (95% CI: -£7546, -£5973) and between 
aflibercept and bevacizumab £7984 (95% CI: £7209, £8759). Bevacizumab was 
dominant when compared to ranibizumab and aflibercept. Aflibercept had an ICER of 
£283595 when compared to ranibizumab, with probability of cost-effectiveness of 
0.04 at the £20,000 per QALY threshold. The conclusions regarding cost-
effectiveness were unchanged in all sensitivity analyses. 
 
Conclusions 
Bevacizumab is an economically attractive alternative to ranibizumab and aflibercept 
for the treatment of MO due to CRVO, because of its lower costs and similar effect 
on patient HRQoL. Bevacizumab is currently unlicensed but its adoption could result 
in substantial savings to healthcare systems around the world. 
